Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

被引：0

作者：

Shustov, Andrei R. ^{[1
,2
]}

Al-Ali, Haifa Kathrin ^{[3
]}

Wulf, Gerald ^{[4
]}

Hsu, Pamela ^{[5
]}

Choi, Mi Rim ^{[5
]}

Allen, Lee F. ^{[5
]}

Visser, Otto J. ^{[6
]}

Zachee, Pierre ^{[7
]}

Horwitz, Steven M. ^{[8
]}

机构：

[1] Seattle Canc Care Alliance, Seattle, WA USA

[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[3] Univ Leipzig, D-04109 Leipzig, Germany

[4] Univ Gottingen, D-37073 Gottingen, Germany

[5] Spectrum Pharmaceut, Irvine, CA USA

[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[7] ZNA Stuivenberg, Antwerp, Belgium

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
Foss, Francine M.
Pro, Barbara
Prince, H. Miles
Sokol, Lubomir
Greenwood, Matthew
Caballero, Dolores
Horwitz, Steven M.
Coiffier, Bertrand
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Rashidi, Armin
Cashen, Amanda F.
FUTURE ONCOLOGY, 2015, 11 (11) : 1659 - 1664
[3] Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Campbell, Peter
Thomas, Christan M.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 143 - 147
[4] Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
Sawas, Ahmed
Radeski, Dejan
O'Connor, Owen A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 202 - 208
[5] Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Bodiford, Andrew
Bodge, Megan
Talbott, Mahsa S.
Reddy, Nishitha M.
ONCOTARGETS AND THERAPY, 2014, 7 : 1971 - 1977
[6] Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
O'Connor, Owen A.
Masszi, Tamas
Savage, Kerry J.
Pinter-Brown, Lauren C.
Foss, Francine M.
Popplewell, Leslie
Cashen, Amanda F.
Doorduijn, Jeanette
Chawla, Shanta
Knoblauch, Poul
Zinzani, Pier Luigi
Brown, Peter
Hess, Georg
Van Hoof, Achiel
Horwitz, Steven M.
Shustov, Andrei R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Lee, Hyon-Zu
Kwitkowski, Virginia E.
Del Valle, Pedro L.
Ricci, M. Stacey
Saber, Haleh
Habtemariam, Bahru A.
Bullock, Julie
Bloomquist, Erik
Shen, Yuan Li
Chen, Xiao-Hong
Brown, Janice
Mehrotra, Nitin
Dorff, Sarah
Charlab, Rosane
Kane, Robert C.
Kaminskas, Edvardas
Justice, Robert
Farrell, Ann T.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2666 - 2670
[8] Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate
O'Connor, Owen A.
Marchi, Enrica
Volinn, Weining
Kim, Won Seog
BLOOD, 2016, 128 (22)
[9] A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01
Foss, Francine M.
Porcu, Pierluigi
Horwitz, Steven M.
Izutsu, Koji
Ishitsuka, Kenji
Kato, Kazunobu
Jin, Jin
Du, Yining
Inoue, Ai
BLOOD, 2021, 138
[10] Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat
Savage, Kerry J.
Horwitz, Steven M.
Zinzani, Pier Luigi
Van Hoof, Achiel
Assouline, Sarit E.
Bhat, Gajanan
Choi, Mi Rim
Allen, Lee F.
Ben-Yehuda, Dina
Jurczak, Wojciech
Masszi, Tamas
Shustov, Andrei R.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →